University of Wollongong

Research Online
Faculty of Social Sciences - Papers

Faculty of Arts, Social Sciences & Humanities

2015

Upper limb spasticity management for patients who have received
Botulinum Toxin A injection: Australian therapy practice
Anne Cusick
University of Wollongong, acusick@uow.edu.au

Natasha Lannin
La Trobe University, N.Lannin@alfred.org.au

Bianca Kinnear
University of Wollongong, bzk222@uowmail.edu.au

Follow this and additional works at: https://ro.uow.edu.au/sspapers
Part of the Education Commons, and the Social and Behavioral Sciences Commons

Recommended Citation
Cusick, Anne; Lannin, Natasha; and Kinnear, Bianca, "Upper limb spasticity management for patients who
have received Botulinum Toxin A injection: Australian therapy practice" (2015). Faculty of Social Sciences
- Papers. 1361.
https://ro.uow.edu.au/sspapers/1361

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

Upper limb spasticity management for patients who have received Botulinum
Toxin A injection: Australian therapy practice
Abstract
Background/aim To describe Australian physiotherapy and occupational therapy practice for patients who
receive upper-limb Botulinum Toxin-A (BoNT-A). Method Anonymous online survey asking about practice
experience. Convenience sample of 128 BoNT-A experienced occupational therapists and
physiotherapists. Results The primary work setting was multidisciplinary inpatient or outpatient
rehabilitation services where therapists had automatic referral to BoNT-A patients. Patients expected
BoNT-A to improve functional movement, reduce hypertonicity, increase passive range, reduce pain,
improve appearance and hand hygiene. Most patients were injected in multidisciplinary public hospital
clinics and had median 2 pre-injection (range 0-30) and 8 post-injection (range 0-50) therapy sessions.
Biceps, flexor digitorum profundus/superficialis and brachoradialis were most frequently injected.
Injectors used therapist assessment information to select sites 68% of the time; only 44% of services had
assessment protocols. Standardised therapy assessments examined motor performance, pain and
function in that order of frequency. The greater the awareness and perceived relevance of an assessment
the more often therapists used it. All therapists set goals, most collaboratively, and these mirrored patient
expectations. The most common treatments were stretch, task-specific functional training, strength
training and home programmes. Conclusion While trends in Australian assessment, goals and treatment
practice were observed, greater consistency could be achieved if therapy practice guidelines existed. The
gap is exacerbated by the absence of Australian BoNT-A organisation and process of care spasticity
management guidelines. This creates an environment where practice variability is inevitable.
Recommendations to improve local service quality are made.
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INTRODUCTION
Upper limb spasticity is a common consequence of neurological events such as stroke.
Spasticity is “a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes
(muscle tone) with exaggerated tendon jerks, resulting from hyper excitability of the stretch reflex”
(Lance,1980,p.485). It emerges over time (Lundström, Smits, Terént, & Borg,2010), and can have
devastating effects on quality of life through associated pain, limitations to passive and active
movement, threats to skin integrity, difficulties in self-care and limb hygiene and in the long term, the
potential for fixed contracture (Kong, Chua, & Lee,2010; Stevenson,2010). Traditional occupational
therapy and physiotherapy approaches to spasticity management have, more recently, been
augmented by pharmacotherapy such as Botulinum toxin –A (BoNT-A) injections. BoNT-A has been
demonstrated to be safe and effective in reducing focal spasticity in a range of neurological conditions
(Delgado, Hirtz, Aisen et al.,2010; Muller, Cugy, Ducerf et al.,2012; Simpson, Gracies, Graham et
al.,2008). In Australia, the National Stroke Foundation (NSF) does not recommend BoNT-A for
everyone with spasticity, rather, for those patients who have persistent moderate to severe spasticity
that “interferes with activity or personal care” (NSF,2010)(Guide 7.3b). BoNT-A injection for post-stroke
upper limb spasticity in Australia is subsidized through the government Pharmaceutical Benefits
Scheme (PBS) “S100 Botulinum Toxin Program criteria for availability”. To be eligible a patient with
upper limb post-stroke spasticity requires an:“MAS greater than or equal to 3 using modified Ashworth scale …as second line therapy when
standard management has failed … or as an adjunct to physical therapy … [BoNT-A] treatment
should be discontinued if the patient does not respond (decrease of MAS greater than 1 in at
least one joint) after two treatments” (Department of Human Services Australian Government,
2012).
Injection can only be done by a medical practitioner in Australia and this is usually a neurologist or
rehabilitation physician.
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BoNT-A for spasticity management can be used in isolation but researchers and peak
rehabilitation bodies recommend multidisciplinary organisation of services and processes for care
(Ozcakir & Sivrioglu,2007; Quinn, Paolucci, Sunnerhagen et al.,2009; Royal College of Physicians,
British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered
Physiotherapists Interested in Neurology,2009; Sheean et al., 2010; Turner-Stokes & Ward 2009;
Wissel, Gracies, Graham et al.,2008). Multidisciplinary BoNT-A spasticity management processes of
care should include the following elements: managing patient expectation, developing functional goals,
using treatment plans and outcome measures, ensuring post-injection therapy review, implementing
post-review treatment planning and providing self-management support (Allison & Knapp,2012). To
date little information about processes of care as evidenced by practice patterns is available (eg.,
Williams, Olver, De Graff, & Singer,2012 is the only study to date on Australian therapy BoNT-A related
practice); and as yet practice guidelines for BoNT-A related therapy assessment and treatment have
not been developed (Levy, Giuffrida, Richards et al.,2007; Sun, Hsu, Sun et al.,2010; Weber, Skidmore,
Niyonkuru et al.,2010). Evidence regarding post-stroke treatment effects in multidisciplinary spasticity
management is also limited (Demetrios, Khan, Turner-Stokes, Brand & McSweeney,2013). This study
helps fill these evidence gaps by exploring BoNT-A related therapy practice in Australia, augmenting
previous work (Williams et al., 2012), by extending enquiry into factors relating to the organisation and
process of care including injection and therapy settings, referral arrangements, muscles injected,
assessments used and goal setting. Background information relating to these factors is now briefly
reviewed.
Muscles injected: Currently, there are no Australian BoNT-A spasticity management guidelines
to inform physician injection decisions. The Australasian Faculty of Rehabilitation Medicine
(AFRM)(2009a) has only one position statement relating to use of BoNT-A (AFRM,2009b); this dates
back to 1997 and it is not specific to spasticity management in adults. Although international BoNT-A
spasticity management guidelines are available, the AFRM does not appear to have appraised or
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endorsed them. Australian injectors therefore set their own BoNT-A spasticity management standards
and determine their own processes for site selection and post-injection follow-up. Injector preference,
not factors such as patient goals or severity of spasticity, have been shown to underpin BoNT-A muscle
site selection in Australia (Baguely, Nott, Turner-Stokes et al.,2011).
Goals and Goal setting: Spasticity management should be goal directed and these goals
should address function (NSF, 2010; Quinn et al.,2009; Royal College of Physicians et al,2009; Sheean
et al.,2010; Turner-Stokes & Ward,2009; Wissel et al.,2010). Goal-setting that involves patients,
carers, therapists and physicians is also recommended (Allison & Knapp,2012; Royal College of
Physicians et al.,2009). Goal types can differ in frequency depending on spasticity recovery stage
(Bakheit, Zakine, Maisonobe et al.,2010; Royal College of Physicians et al.,2009; Williams et al.,2012).
In the early months of recovery the most common goal for BoNT-A treatment is active functional
recovery, but in chronic spasticity management it is passive function. Pain relief is a common goal in
both early and chronic spasticity conditions.
Assessments: Assessment should help inform goal setting and evaluation of goal attainment.
Standardised functional assessments are however, rarely used in BoNT-A related therapy (Bakheit et
al.,2010; Williams et al.,2012). Instead, one Australian study found goal achievement was measured
through patient or family self-report, standardised outcome measures that may not reflect activities of
daily living, or non-standardised assessments (Williams et al.,2012).
Treatment modalities: Therapy treatment for BoNT-A patients includes physical modalities
(such as sustained stretch using serial casting, orthoses, taping/strapping), strengthening, forced use
motor training (constraint-induced movement therapy), repetitive task specific practice and/or mental
practice, “movement based therapy”, home exercise programs, electrical stimulation to agonist and
injected muscles, and adaptation of activities or the environment to prevent and minimize adverse
impact of spasticity on function (Ada, Dorsch, & Canning,2006; Demetrios et al.,2013; Katalinic, Harvey,
Herbert et al.,2010; Page, Murray, & Hermann,2011; Treger, Aidinof, Lehrer, & Kalichman,2012;
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Williams et al.,2012). Currently there are no modality-specific guidelines for treatment type, frequency
or duration, nor is much known about current practice. Evidence of multidisciplinary rehabilitation effect
is considered limited in scope and of low quality (Demetrios et al.,2013). To date there has been debate
about BoNT-A’s contribution to attainment of functional goals (Caty, Detrembleur, Bleyenheuft et
al.,2009; Cousins, Ward, Roffe et al.,2001; Delgado et al.,2010; Francis, Wade , Turner-Stokes et
al.,2004; Galvin & Sakzewski,2011; Lai, Francisco, & Willis,2009; Patel,2011; Rosales, Kong, Goh et
al.,2002). At the same time there has been promising evidence that BoNT-A plus therapy may have
sustained positive effects in spasticity reduction (Katalinic et al.,2010; Wolf, Milton, Reiss et al.,2012)
and functional outcomes (Ada et al.,2006; Page et al.,2011; Treger et al.,2012).

METHODS
This study aims to describe current Australian spasticity management practice by outlining the
organisation and processes of care from a therapist perspective. To do this, an online anonymous selfreport survey was conducted with therapists who responded to a study invitation distributed through
informal neuro-rehabilitation occupational therapy and physiotherapy networks in Australia. Recruitment
took place after approval of researcher institutional research ethics committees. The study invitation
specified that participants needed to be working in Australia, have upper limb neurological rehabilitation
experience in the past five years, and experience working in services where patients had received
BoNT-A injections.
The author-designed survey asked demographic and clinical experience questions.
Organisation of BoNT-A care was explored through questions about: proportion of neuro-rehabilitation
caseload that received BoNT-A, injection setting, referral process, patient access to therapy, therapy
setting and service type. Processes of BoNT-A therapy care were examined by questions about: patient
expectations; muscles injected; assessments used (rated as: not heard of it, never, rarely, sometimes,
often, always); assessment relevance (rated as: don’t know, essential must be included important,
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acceptable, marginal, not relevant shouldn’t be included)(scale adapted from Clemson, Fitzgerald &
Heard,1999; Skakun & King,1980); injector use of assessment information in site selection; whether or
not the service had an assessment protocol; goal-setting; goals set (rated on: never, rarely, sometimes,
often always); and treatment modalities used (rated on: never, rarely, sometimes, often, always). Even
though BoNT-A cannot reduce contracture this was included in the goal questions because anecdotally
it was reported to be in use.
Responses were submitted by participants into Survey Monkey™ and data was imported to
SPSS Version 20 (IBM, 2011). A value was allocated to Likert-type responses (higher values to higher
ratings; not heard of it and don’t know reported separately); item values were summed and then ranked
to show trends. Comments were invited regarding other goals and whether or not all patients who
receive BoNT-A receive therapy. Comments with the same or similar wording were grouped together so
the range of the responses could be reported. In the case of patient expectations, the number of
responses in each category was tallied to show trends. No question in the survey was compulsory.
Missing items are noted in the text or tables.
RESULTS
All participants (n=128) were university qualified; aged between 23 and 60 years (mean 33.5; median
32; SD 7.8). They were predominantly female occupational therapy clinicians working in capital cities in
inpatient or outpatient rehabilitation services (Table 1). Only 27.9% (n=33) worked some or all of the
time in a BoNT-A clinic (n=85, 72% did not; n=10 missing). Most had worked with 10 or less BoNT-A
injection patients in their career and 10% or less of their neurology caseload were injected patients.
Overall, participants (n=127) had significant total career (mean 11.5, median 10, SD8.1, range 1.5 to 40
years) and neurology (mean 8.9, median 7, SD7.8, range 7 months to 35 years) clinical experience. For
most of the n=122 respondents, years of BoNT-A experience were less than half that of their neurology
experience (mean 4.12, median 3, SD3.26, range 3 months to 15 years). In the past 12 months, 91.4%
5

had seen neurological patients who had received upper limb BoNT-A injections and 58.6% had current
BoNT-A patients.
Organisation of care
Overwhelmingly, BoNT-A injections were provided in public hospital BoNT-A spasticity management
clinics (72%), with half of the patients receiving injections in multidisciplinary services (49.5%); a quarter
were given in physician-only services (28.5%)(Table 2). Most therapists (58.5%) reported they could
choose when they saw injected patients. Setting-specific automatic therapy referral known as “blanket
referral” accounted for 23% (Table2). Participants were asked whether they thought all patients who
had received BoNT-A injections received therapy and most said “no” (n=68 of 81 respondents; 84%).
Participants commented on issues they thought related to therapy access (Table 3); timely referral and
team communication were important.
Process of care
Injections: Therapists reported most of their BoNT-A patients were ‘first –time’ BoNT-A
recipients, (only 34% had repeat injections). Of 26 different upper limb muscles, participants reported
that biceps, flexor digitorum profundus/ superficialis and brachoradialis were the most frequently
injected (Table 4). Those muscles at the top of the ‘never injected’ list were in descending order,
rhomboids, extensor digitorum,and extensor carpi ulnaris. The muscles most often ‘not known’ about by
therapists were levator scapulae and subscapularis.
Assessments: Most participants reported their clinic/workplace did not have assessment
protocol they had to use (47.5%, n=61), 37% did (n=48) (n=19, 15% missing); but the overwhelming
majority did assess their patients (all but 6 of 90 respondents; n=38 missing) before and after injection
(n=60,67%).. Most therapists thought physicians used their assessment findings always or sometimes
to select injection sites (n=61, 67.7%). Assessment awareness and frequency of use is presented in
Table 5(footnote includes citations). All had heard of range of motion/goniometry, only one had not
6

heard of the Modified Ashworth Scale or Ashworth Scale, two the manual muscle test, Barthel Scale
and Motor Assessment Scale, and three the Goal Attainment Scale. The most frequently used
assessments in order were range of motion (highest), next Modified Ashworth Scale, the Tardieu,
Manual Muscle test, Modified Tardieu Scale, Motor Assessment Scale, the Pain Visual Analogue Scale,
and then Goal Attainment Scaling. In general terms, greater use mirrored greater assessment
awareness and perceived relevance.
Patient expectations: N=104 respondents described what they thought patients expected from
their BoNT-A injection. In order from most to least frequent they were “active/functional movement/
dexterity” (n=43; 41.3%), improvement in hypertonicity/ tightness (n=19; 18.3%), increased passive
range (n=18, 17.3%), reduction in pain (n=16; 15.4%), enhanced appearance (n=12, 11.5%), and
improved hygiene (n=9, 8.6 %).
Goals: Participants (n=83; 45 missing) set goals either with (97.6%, n=81) or independent of
(2.4%, n=2) patients and just over half of all patients had goals set before they were injected. There
was a pattern in goal use: least used was increased upper limb dexterity, in increasing frequency was
enhanced occupational therapy or physical therapy,enhanced cosmetic appearance of the upper limb,
reduced contracture, increased upper limb active movement, reduced pain, and enhanced hygienic
care was the most frequently used. N=47 participants identified other goals: the most frequent one,
“enhanced function”, was usually qualified with the descriptor “task specific”. Some participants gave
examples of these tasks (eg., dressing) or indicated that tasks were identified by patients. Other goals
were: (a) to enhance position or posture, upper limb movement patterns, repetitive reciprocal exercise,
tolerance of and ability to wear orthoses, balance and gait safety and/or sleep through decreased pain;
(b) maintain range of movement and/or joint integrity; (c) prevent contracture deterioration; and (d)
decrease care-giver burden.
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Treatment modalities: Nine treatment modalities were rated from never to always used (n=85;
43 missing). In order from low to high use they were: biofeedback, orthotic casts, electrical stimulation/
functional electrical stimulation, orthotic splints, movement training, home programs, strength training,
task specific functional training and stretch. Sixteen therapists reported they used other treatments (a)
constraint induced movement therapy, (b) task and strength movement training, (c) weight bearing
stretches, (d) therapeutic positioning, (e) general fitness program and (f) compensation training for
functional activities
Treatment session frequency: Most patients were reported to receive pre-injection (mean
3.8,median 2, SD5.99, range 0 to 30 sessions; n=18, 24% had no pre-injection therapy) and postinjection sessions (mean 10.2,median 8, SD9.57, range 0 to 50; n=6, 5.6% had no post-injection
therapy). To calculate the number of therapy sessions the following decision rules were used because
participants answered the question in a variety of ways. In the case of pre-injection therapy sessions:
(a) n=67 participants gave a numerical estimate which was used; (b) n=5 gave a range and in this case
the highest or the highest aggregate was used, eg. “1-6” was reported as 6 sessions while “1-6 weeks
of 3-5 sessions/week” was reported as the function of 6 weeks by 5 sessions per week thus 30
sessions; (c) n=6 gave a weekly range eg., “3-5 per week”, but because the number of weeks was not
specified, a total could not be estimated so data was treated as missing;(d) n=31 gave no estimate but
instead gave a description such as “variable/varies”=13, “daily”=5, “depends”=3, or some other
word=10 such as “routine”, “lots”, “many”, “several” and these were also treated as missing data; (e)
n=19 did not answer. Thus 56 of 128 pre-injection therapy responses were treated as missing data. In
the case of post-injection therapy sessions the same ‘rules’ applied: (a) n=44 gave a numerical
estimate; (b) n=25 gave a range; (c) n=9 gave a weekly range but did not specify number of weeks; (d)
n=26 gave a descriptor instead of an estimate eg., “variable/varies”=5, “depends”=4;; (e) n=24 did not
answer. Thus 59 of 128 post-therapy responses were treated as missing data.
DISCUSSION
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At present Australian therapists must practice in the absence of national BoNT-A spasticity
management guidelines and without therapy-specific guidelines in particular. This is a challenge given
our findings that BoNT-A therapy was both exceptional and relatively new for most therapists.
‘Exceptional’ in that most therapists had seen few BoNT-A patients in their careers and the proportion
of their caseload receiving BoNT-A was small. ‘New’ in that most therapists had BoNT-A years of
experience that were less than half that of their neurology practice. The practice variability we observed
may be a consequence of this infrequent and relatively new exposure. But equally it may result from
varying local approaches to care developed without AFRM guidance regarding ‘model’ processes and
organizational arrangements for multidisciplinary care. One participant comment illustrates current
gaps:Most adult patients I have had experience with rarely see a therapist pre-injection. They also rarely
receive post-injection therapy. If patients do have access to therapy services it is extremely uncommon
that the therapist has the required skills to provide appropriate interventions such as casting, splinting
and movement based interventions. The most significant issue is related to the model of service
delivery for adults with a disability. Patient follow-up and monitoring over time is completely inadequate
and patients are given their immediate post injection therapy and discharged. This is not appropriate for
this patient population as their complex impairments need ongoing review and intervention

Australian guidelines for BoNT-spasticity management and therapy specific guidelines are urgently
required. Guidelines will provide a national benchmark for local practice improvement. Meanwhile
therapists can improve their own process of care through professional development and consider
implementing quality improvement activities to enhance local organization of care. The following
recommendations provide a starting point for change.
This study demonstrated that most of the time, spasticity management was through
multidisciplinary ‘shared care’ (NSF,2010; Wissel et al.,2008). But a minority reported this NSF
recommendation was not implemented, with physicians injecting without referring to therapy, or the
absence of a coordinated goal directed approach (Royal College of Physicians et al.,2009; Sheean et
al.,2010). Multidisciplinary team communication, a feature of good quality care (NSF Guide 1.8) was
also reported to be problematic in a minority of services, particularly in relation to physician-therapist9

patient communication about patient expectations, functional goals, and injection site selection and
follow up. The AFRM identifies a key function of rehabilitation physicians is to provide “coordinated and
patient-focused program[s] of individual, goal directed rehabilitative care” (AFRM, 2009c). Team
communication would appear to be central to achieving this. Local strategies targeting team
communication could be implemented to help physicians fulfil the coordination function in relation to
BoNT-A spasticity management.
There is promising evidence that BoNT-A plus therapy achieves positive results (Ada et
al.,2006; Katalinic et al.,2010; Page et al.,2011; Treger et al.,2012; Wolf, Milton, Reiss et al.,2012), but
participants reported that injected patients do not always receive therapy. Local strategies to encourage
and streamline therapy referral should be developed. Service organization could be improved by
providing sufficient therapy resources to meet demand of BoNT-A injected patients. If therapy cannot
be provided, services need to consider whether funds spent on BoNT-A alone are a wise spasticity
management investment.
Services also need to consider whether the timing and amount of therapy they provide is
appropriate and adequate. The NSF Guide 6.1.1a (NSF, 2010) recommends as much practice as
possible within the first six months of stroke, unfortunately our study did not examine when therapy
occurred in relation to the stroke. NSF Guide 6.1.1b (NSF, 2010) recommends at least one hour
therapy per day at least five days a week for patients in ‘active rehabilitation’; unfortunately our study
did not examine service arrangements for therapy sessions. But our study did obtain an estimate of the
number of therapy sessions patients typically received which was pre-injection mean 3.8 (median 2)
post-injection mean 10.2 (median 8) and a quarter of participants reported no pre or post therapy.
Services should ensure that the number of pre- and post-injection therapy sessions, their timing in
relation to the stroke event and their duration is monitored to help build an evidence base for future
investigation.
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Processes of care could be improved at a local level through development of service protocols
for referral, assessment, site selection, goal setting, treatment and follow-up. Timing and type of referral
varied in this study; greater consistency could minimize barriers to patient access to therapy when it is
available. Injector use of assessment findings also varied – some chose sites unrelated to assessment
findings and goals. Service protocols that encourage a link between assessment findings,
collaboratively developed functional goals (Royal College of Physicians et al.,2009; NSF Guide 1.4.2b ;
Wissel et al.,2008; Turner-Stokes et al., 2009) and injection site selection would help facilitate a patient
centered approach to spasticity management.
Processes of care could also be improved through professional development. Most services did
not have assessment protocols and some participants did not use standardized assessments. While all
participants set goals and most were functional, not all used functional assessments. The most
frequently used assessments encompassed motor performance followed by pain and function. Greater
use of standardized assessments, and functional assessments in particular would improve evidencebased decision-making and goal setting. Professional development may be required to enhance
therapist knowledge of and skill in standardized functional assessment selection, administration and
interpretation. This could be supported by service adoption of assessment protocols. One assessment
illustrates the urgent need for professional development in assessment knowledge and skill. When
compared with Williams et al. (2012) our sample had better uptake of the MAS, as only 45.7% of their
sample used it. But given the critical role of the MAS as a threshold measure for PBS subsidy it would
be expected that 100% of therapists should have used it and this was not the case. Australian
therapists have previously reported their BoNT-A training was ad-hoc, gained through “lecture, seminar
or workshop [attendance] related to Botulinum toxin injections and spasticity management” (Williams et
al., 2012, p.259). This further reinforces the need for targeted professional development.
Processes of care could also be improved by services developing local treatment protocols and
professional development to enhance therapist capacity in administering treatment modalities. The
11

most common interventions in this study were recommended modalities: stretch (Demetrios et
al.,2013), strength training (Guide 6.2.2), movement training and task-specific functional training
(Guide 6.3.5a and b; Guide 6.4b), but consistency in approach is lacking without therapy guidelines.
Local treatment protocols may fill that gap. Home programs were also common but as a modality they
are opaque: services need to make explicit what is in them, frequency, duration and intensity
particularly in relation to NSF Guides 6.1.1e and 6.3.5a that relate to practice. Services can also
describe why some recommended treatments are not used. CMIT, for example is supported by the NSF
Guide 6.3.5a, but barriers to use have been identified (Viana & Teasell, 2012).
Limitations: This study was limited by the self-report, anonymous and convenience sampling
design. The survey itself brought limitations because it was not standardized and subsequent analysis
of results has revealed gaps and problems in data coding that weaken the study. While all therapists
provided demographic and most provided clinical setting responses, there were many missing
responses – especially at the point in the survey where participants were asked to use Likert-type
scales to rate multiple items. Between a quarter and a third of participants did not respond to ratings
even though all participants continued “clicking through” survey pages so they could submit. Response
drop may have been due to responder fatigue, time pressures, or questions could have been difficult to
answer if participants were not aware of organization of services at their workplace, or if they or their
service did not know about or use the range of assessments, goals and treatments identified.
In conclusion, although BoNT-A therapy practice varies in Australia, trends were evident. On
the whole, if patients are referred for therapy, most will have a multidisciplinary team providing
coordinated care in a publicly funded inpatient or outpatient rehabilitation setting. Patients will have
treatment goals set collaboratively, and these will reflect patient expectations and will focus on function.
Standardized assessments will normally be used and assessments will collect information about patient
motor performance, pain and function. Most patients will have home programs, but we don’t know what
these entail. Patients will receive therapy treatments that are generally consistent with NSF
12

recommendations; however interventions lack strong evidence of effect. On the whole patients will
receive more therapy sessions after injection than before, but more research is needed regarding
session timing, frequency and duration. Development of Australian spasticity management guidelines
or endorsement of international guidelines by peak professional bodies will provide a useful national
benchmark for practice. Therapy guidelines can then be developed in a context where standards for
organisation and processes of spasticity care are clear.
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References
Ada, L., Dorsch, S., & Canning, C.G. (2006). Strengthening interventions increase strength and
improve activity after stroke: a systematic review. Aust J Physiother, 52, 241-248. Retrieved
from: http://www.ncbi.nlm.nih.gov/pubmed/17132118
Allison, R. & Knapp, K.M. (2012). Spasticity management with botulinum toxin: development and
evaluation of a tool for audit. J Rehabil Med,44, 558-561. doi: 10.2340/16501977-0977
Australasian Faculty of Rehabilitation Medicine, (2009a). The Royal Australasian College of Physicians
–Home Page. Retrieved from http://www.racp.edu.au/page/racp-faculties/australasian-faculty-ofrehabilitation-medicine
Australasian Faculty of Rehabilitation Medicine, (2009b). Consensus statement BOTULINUM TOXIN
(1997) - UNDER REVIEW. Retrieved from http://www.racp.edu.au/index.cfm?objectid=02A28582E795-54CF-2A8041E0BD658E1E
Australasian Faculty of Rehabilitation Medicine, (2009c). Position Statement Rehabilitation Medicine
Scope of Practice (Adult Rehabilitation Medicine) (2011). Retrieved
from http://www.racp.edu.au/index.cfm?objectid=02A28582-E795-54CF-2A8041E0BD658E1E
Baguely, I.J., Nott, M.T., Turner-Stokes, L., De Graaff, S., Katrak, P., McCrory, P.et al. (2011).
Investigating muscle selection for botulinum toxin-A injections in adults with post-stroke upper limb
spasticity. J Rehabil Med, 1032-1037. doi: 10.2340/16501977-0885
Bakheit, A.M., Zakine, B., Maisonobe, P., Aymard, C., Fhedoroff, K., Hefter, H. et al. (2010). The profile
of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A:
an international survey. Int Rehabil Rehab Res, 33, 199-204. doi: 10.1097/MRR.0b013e328332f5e0
Caty, G.D., Detrembleur, C., Bleyenheuft, C., Deltombe, T., & Lejeune, T.M. (2009). Effect of Upper
Limb Botulinum Toxin Injections on Impairment, Activity, Participation, and Quality of Life Among Stroke
Patients. Stroke, 40, 2589-2591. doi: 10.1161/STROKEAHA.108.544346
Clemson, L., Fitzgerald M., & Heard, R. (1999).Content validity of an assessment tool to identify home
fall hazards: The Westmead Home Safety Assessment. British Journal of Occupational Therapy, 62,
171-179.
Cousins, E., Ward, A., Roffe, C., Rimington, L., & Pandyan, A. (2001). Does low-dose botulinum toxin
help the recovery of arm function when given early after stroke? A phase II randomized controlled pilot
study to estimate effect size. Clin Rehabil, 24, 501-513. doi: 10.1177/0269215509358945
Delgado, M.R., Hirtz, D., Aisen, M., Ashwal, S., Fehlings, D.L., McLaughlin, J. et al. (2010). Practice
Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an
evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of
Neurology and the Practice Committee of the Child Neurology Society. Neurology, 74, 336-343. doi:
10.1212/WNL.0b013e3181cbcd2f
Demetrios, M., Khan, F., Turner-Stokes L., Brand C.,& McSweeney S. (2013). Multidisciplinary
rehabilitation programmes following treatment of spasticity after stroke. Cochrane Review.
DOI: 10.1002/14651858.CD009689.pub2
1

Department of Human Services Australian Government, (2012). Botulinum toxin.Retrieved
from http://www.pbs.gov.au/medicine/item/6103F.
Francis, H.P., Wade, D.T., Turner-Stokes, L., Kingswell, R.S., Dott, C.S.,& Coxon, E.A. (2004). Does
reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg
Psychiatry, 75, 1547-1551. Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/15489384
French, B., Thomas, L., Leathley, M., Sutton, C., McAdam, J., Forster, A. et al. (2010). Does repetitive
task training improve functional activity after stroke? A Cochrane systematic review and meta-analysis.
Journal of Rehab Medicine, 42, 9-14. doi: 10.2340/16501977-0473
Galvin, J. & Sakzewski, L. (2011). Botulinum toxin A in conjunction with occupational therapy reduces
spasticity and improves upper limb function and goal attainment in children with cerebral palsy. Aust
Occup Ther J, 58, 132-133. doi: 10.1111/j.1440-1630.2011.00925.x
IBM Corp, (2011). IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM CorpIBM Corp.
Released 2011.
Kaňovský, P., Slawek, J., Denes, Z., Platz, T., Comes, G., Grafe, S. et al. (2011). Efficacy and safety of
treatment with Incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT
201) in post-stroke upper limb spasticity. J Rehabil Med, 43, 486-492. doi: 10.2340/16501977-0796
Katalinic, O.M., Harvey, L.A., Herbert, R.D., Mosely, A.M., Lannin, N.A., & Schurr, K. (2010). Stretch for
the treatment and prevention of contractures. Cochrane Database of Systematic Reviews 2010.
Retrieved
from http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007455.pub2/abstract;jsessionid=1570E3F
408A1458B45C29321C1B660EB.d03t04
Kong, K.H., Chua, K.S., & Lee, J. (2010). Symptomatic upper limb spasticity in patients with chronic
stroke attending a rehabilitation clinic: Frequency, clinical correlates and predictors. J Rehabil Med, 42,
453-457. doi: 10.2340/16501977-0545
Lai, J.M., Francisco, G.E., & Willis, F.B. (2009). Dynamic splinting after treatment with botulinum toxin
type-A: a randomized controlled pilot study. Adv Ther, 26,241–248. doi: 10.1007/s12325-008-0139-2
Lance JW (1980). Symposium synopsis. In Spasticity: Disordered Motor Control. Edited by Feldman
RG, Young RR, Koella WP. pp. 485–494 Miami: Symposia Specialists.
Levy, C.E., Giuffrida, C., Richards, L., Wu, S., Davis, S., & Nadeau, S.E. (2007). Botulinum toxin a,
evidence based exercise therapy, and constraint induced movement therapy for upper limb
hemiparesis attributable to stroke: a preliminary study. Am J Phys Med Rehabil, 86, 696-706. Retrieved
from: http://www.ncbi.nlm.nih.gov/pubmed/17709993
Lundström, E., Smits, A., Terént, A., & Borg, J. (2010). Time-course and determinants of spasticity
during the first six months following first-ever stroke. J Rehabil Med, 42, 296-301. doi:
10.2340/16501977-0509

2

Muller, F., Cugy, E., Ducerf, C., Dellici, C., Guehl, D., Joseph, A. et al. (2012). Safety and self-reported
efficacy of botulinum toxin for adult spasticity in current clinical practice: a prospective observational
study. Clin Rehabil, 26,174-179. doi: 10.1177/0269215511412799
National Stroke Foundation. (2010). Clinical Guidelines for Stroke Management 2010 Retrieved
from http://www.strokefoundation.com.au
Ozcakir, S. & Sivrioglu, K. (2007). Botulinum Toxin in Poststroke Spasticity. Clin Med Res, 5, 132138. doi: 10.3121/cmr.2007.716
Page, S.J., Murray, C., & Hermann, V. (2011). Affected upper-extremity movement ability is retained 3
months after modified constraint-induced therapy. Am J Occup Ther, 65, 589-593. Retrieved
from: http://www.ncbi.nlm.nih.gov/pubmed/22026327
Patel, A.T. (2011). Successful treatment of long term, post-stroke upper limb spasticity with
onabotulinum toxin A. PhysTher, 91,1636-1641. doi: 10.2522/ptj.20100370
Quinn, T.J., Paolucci, S., Sunnerhagen, K.S., Sivenius, J., Walker, M.F., Toni, D. et al. (2009).
Evidence-based stroke rehabilitation: an expanded guidance document from the european stroke
organisation (ESO) guidelines for management of ischaemic stroke and transient ischaemic attack
2008. J Rehabil Med, 41, 99-111. doi: 10.2340/16501977-0301
Rosales, R.L., Kong, K.H., Goh, K.J., Kumthornthip, W., Mok, V.C.T., Delgado-De Los Santos, M.M. et
al. (2012). Botulinum Toxin Injection for Hypertonicity of the Upper Extremity Within 12 Weeks After
Stroke: A Randomized Controlled Trial. Neurorehabil Neural Repair, 26, 812-821.
Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of
Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. (2009). Spasticity in
adults: management using botulinum toxin: national guidelines London, RCP. Retrieved
from http://www.rcplondon.ac.uk/sites/default/files/documents/spasticity-in-adults-managementbotulinum-toxin.pdf
Sheean, G., Lannin, N.A., Turner-Stokes, L., Rawicki, B. & Snow, B.J. (2010). Cerebral Palsy Institute.
Botulinum toxin assessment, intervention and after-care for upper-limb hypertonicity in adults:
international consensus statement. Eur J Neurol, 17, 74-93. doi: 10.1177/1545968311430824
Simpson, M.D., Gracies, J.M., Graham, H.K., Miyasaki, J.M., Naumann, M., Russman, B. et al.
(2008).Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review):
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of
Neurology. Neurology, 70, 1691-1698. doi: 10.1212/01.wnl.0000311391.00944.c4
Skakun, E.N. & King, S. (1980). A comparison of several score cutting procedures and their effects on
success rates. Conference on Research in Medical Education, 19, 9-14.
Stevenson, V.L. (2010). Rehabilitation in practice: Spasticity management. Clin Rehabil, 24,293304. doi: 10.1177/0269215509353254
Sun, S.F., Hsu, C.W., Sun, H.P., Hwang, C.W., Yang, C.L., & Wang, J.L. (2010). Combined Botulinum
Toxin Type A with constraint induced movement therapy for chronic stroke patients with upper extremity

3

spasticity: a randomized controlled study. Neurorehabil Neural Repair, 24,34-41. doi:
10.1177/1545968309341060
Treger, I., Aidinof, L., Lehrer, H., & Kalichman, L. (2012). Modified constraint-induced movement
therapy improved upper limb function in subacute poststroke patients: a small-scale clinical trial. Top
Stroke Rehabil, 19, 287-93. doi: 10.1310/tsr1904-287
Turner-Stokes, L. & Ward, A.B. (2009). Guidelines for the use of Botulinum Toxin in the management of
spasticity in adults: Concise Guidance to good practice. Royal College of Physicians, London.
Turner-Stokes, L., Baguley, I.J., De Graaff, S., Katrak, P., Sandanam, J., Davies, L. et al. (2009).
Botulinum toxin A for treatment of upper limb spasticity following stroke: A multi-centre randomized
placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil
Med, 41, 536-544. doi: 10.2340/16501977-0366
Viana, R. & Teasell, R. (2012). Barriers to the implementation of constraint-induced movement therapy
into practice. Top Stroke Rehabil., 19, 104-14. doi: 10.1310/tsr1902-104
Weber, D.J., Skidmore, E.R., Niyonkuru, C., Chang, C., Huber, L.M. & Munin, M.C. (2010). Cyclic
functional electrical stimulation does not enhance gains in hand grasp function when used as an
adjunct to onabotulinumtoxinA and task practice therapy: a single blind, randomized controlled pilot
study. Arch Phys Med Rehabil, 91, 679-686. doi: 10.1016/j.apmr.2010.01.010
Williams, G., Olver, J., De Graff, S., & Singer, B.J. (2012). The use of Botulinum toxin Type A in the
management of adult-onset focal spasticity: a survey of Australian Allied health professionals. Aust
Occup Ther J, 59, 257-264. doi: 10.1111/j.1440-1630.2012.01027.x
Wissel, J., Ward, A.B., Erztgaard, P., Bensmail, D., Hecht, M.J., Lejeune, T.M. et al. (2008) European
consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med, 41,13-25. doi:
10.2340/16501977-0303
Wolf, S.L., Milton, S.B., Reiss, A., Easley, K.A., Shenvi, N.V., & Clark, P.C. (2012). Further Assessment
to Determine the Additive Effect of Botulinum Toxin Type A on an Upper Extremity Exercise Program to
Enhance Function Among Individuals With Chronic Stroke but Extensor Capability , Arch PhysMed
Rehabil. 93, 578-587. doi: 10.1016/j.apmr.2011.10.026

4

Table 1: Demographic Data
Factor
(n of 128 respondents
who answered
question)
Profession
(n=126)
Gender(n=127)
State or Territory
(All Australian
jurisdictions listed)
(n=128)

Geographical Location
of Current Work Setting
(n=114)
Primary Work Role
(n=128)

Primary setting of
current Practice
(n=119)

Number of BoNT-A
patients worked with in
career
(n=128)
Patients in neurology
caseload who received
BoNT-A injection
(n=109)

Categories

% of
respondents

n
Physiotherapist
Occupational Therapist
Female
Australian Capital Territory
New South Wales
Northern Territory
Queensland
South Australia
Tasmania
Victoria
Western Australia
Capital City
Other metropolitan area
Rural
Remote
Clinician
Manager
Academic
Consultant
Researcher
Intensive care unit
Acute hospital inpatient ward
Inpatient rehabilitation service
Outpatient rehabilitation service
Community rehabilitation service
Day Hospital
Private Practice
University clinical research
Spasticity Clinic (in or outpatient not
specified)
Both in and outpatient service
<5
5-10
11-20
21-30
>30

50
76
114
1
43
0
10
7
11
45
11
92
15
7
0
110
8
4
3
3
0
10
41
35
22
4
3
2
1

39.7
60.3
90
1
33.5
0
8
5.5
8.5
35
8.5
81
13
6
0
86
6.5
3
2
2
0
8.5
34.5
29.5
18.5
3.5
2.5
2
1

1
36
37
21
11
25

1
28
29
16.5
8.5
19.5

<1
1 to <5%
5%
<10%
10%
20 25%
30%
40%

6
26
23
6
22
11
5
1

5.5
24
21
5.5
20
10
4.5
1

70%
95%
N/A 2
Comment made no % estimate given

2
2
2
3

2
2
2
2.5

Table 2: Organisation and process of care
Factor
(n of 128 participants
responding)

Category

n

% of
respondents

Setting: Service type for
injection
(n=128)

BoNT-A spasticity Clinic – public hospital
BoNT-A spasticity Clinic- private hospital
BoNT-A spasticity Clinic – private community
service (not hospital)
Public hospital doctor – not in a BoNT-A
clinic
Private hospital doctor – not in a BoNT-A
clinic
Private provider – not in a BoNT-A clinic
Other (Department Veterans Affairs
provider; mixed private public)
Zero
<1
1 to 5%
10%
20 to 25%
30%
50%
70-75%
80-85%
90-95%
100%
Don’t know
Not Applicable
Student Clinic

92
2
1

72
1
1

24

20

5

4

2

1

2
25
1
3
3
4
4
8
3
8
15
30
1
1
1

1
23
1
3
3
3.5
3.5
7.5
3
7.5
14
28
1
1
1

Zero
<1 to 1%
5%
10 to 15%
20%
30 to 40%
50 to 60%
70 to 75%
80%
90 to 95%
100%
Don’t know
Not applicable

35
2
6
12
7
2
6
5
3
6
16
5
1

33
2
5.5
11
6.5
2
5.5
5
3
5.5
15
5
1

“Blanket” referral (anytime)
Sometimes before injection
Sometimes after injection
Sometimes before or after - no pattern
Usually before injection
Usually after injection

19
5
8
10
3
2

23
6
9.5
12
3.5
2.5

Setting: Percentage of
patients who received
their injection in a
multidisciplinary clinic
situation (ie injecting
doctor and OT/Physio)
(n=107)

Service: Percentage of
patients who only see a
private
consultant/doctor at
the time of injection
(n=106)

Service: Timing of
physician referral to
therapy
(n=85)

Service: Timing of
therapy assessment in
relation to injection
(n=90)
Service: Physician use
of therapy assessment
findings to decide
where to inject
(n=90)
Service: Timing of
therapy goals setting in
relation to injection
(n=83)
Service: Percentage of
BoNT-A therapy
patients who have preinjection goal setting
for
(n=86)

Usually before or after - no pattern
No referral for treatment
Usually before injection only
Usually after injection only
Usually Before and after injection
Only sometimes
Never
Yes always
Yes sometimes
Rarely
Never
Don’t know
With patients before injection
With patients after injection
With patients but in no particular pattern
Without patients before injection
Without patients after injection
I do not set goals
Zero
<5 to 5%
20 to 25%
30 to 40%
50%
60 to 65%
70 to 75%%
80%
90 to 95%
99 to 100%
Not applicable

30
8
5
6
60
13
6
30
31
17
6
6
56
9
16
2
0
0
7
8
4
2
5
2
11
10
7
29
1

35.5
9.5
5.5
7
67.5
14.5
5.5
33.3
34.4
18.9
6.7
6.7
68.5
11
18
2.5
0
0
8
9
4.5
2
6
2.5
13
11.5
8
34
1

Table 3: Issues related to therapy access
Issue
Shared care
not
implemented

Example

Physicians inject without referring
to therapy

Participant comment
Some doctors injecting in private room or individual consults do not
refer on

Physicians inject and refer to
therapy after

I often get client[s] referred to me after injections have been done by
a private doctor, where by no client goal setting has been done.

Physicians inject without
consulting team

At times the Dr's have been known to inject pt's [sic] on our wards
with NIL communication with allied health staff.

Physician beliefs about utility of
therapy

I do not believe our Dr's feel that injected pt's [sic] need intensive
therapy to get results, and that is a massive barrier. At times Dr's
have injected different muscles to those recommended by OT/PT we are not always present at injection clinics

Patient beliefs and expectations

It can be viewed by the patient and family, as a quick fix. Not
something which may need intense therapy and home programs to
gain the full benefit from

Injections occur in city; patients
live in regional areas

Some patients in regional areas also receive injections whilst in
Sydney then return to regional area and do not receive follow up

Injections occur in city and
patients live in rural areas

If patients don't live locally, can be … a challenge when many of our
patients live out of area or in rural areas

Discharge care destinations may
not have therapy

Some are nursing home residents with limited access to therapy
They may not be in a facility that has PT and OT

Patients cannot access therapy
centre

Some clients don't come into the centre due to access to the centre.
We do not provide transport unless they cannot make it in with other
means

Waiting lists

Sometimes a delay in getting them booked in due to availability

Short-staffed

PT/OT could be short-staffed

Competing demands

Level of therapy may not be ideal in some situations secondary to
staffing difficulties within an acute setting

BoNT-A therapy unavailable

These [therapy services] are quite sparse and I doubt they receive
the intensity they should

No funding for therapy

In our District we currently have no funding for allied health

Patient prioritizing

We are getting to the stage where we would never be able to see
any other clients if we continued to see the BoNT-A clients forever.
So we are deciding who benefits from [follow-up] treatment by
looking at newly referred clients in assessment sessions preBoNT-A.

Coordinated BoNT-A injection needs
goal directed coordinated follow-up
care not
Goal directed multidisciplinary care
implemented impeded

BoNT-A without follow up (at least advice) is a waste of time for UL
unless it is something really simple like pain relief - which it rarely is

Postinjection
therapy not
available
patients

Therapy staff
inadequate
for demand

Maximise gains of BoNT-A with
therapy

Rehab consultant … He does not include allied health prior to or
during BoNT-A injections so we never get to look at the patient from
a team perspective to see … what the goals might be
If there is enough clinical evidence to provide BoNT-A in the first
place then there are gains to be made for the client and these should
be maximised by therapeutic intervention - preferably a combination
of OT and PT to ensure gains are made in muscle length, muscle
strength, movement patterns, splinting is provided and as well as
placing this into functional movement patterns and translated into
task performance

Table 4: Muscles Injected
Muscle
N=91 responses

Rank of injection
frequency
(lowest=1 to
highest=20)*
1
1
2
3
4
5
5
6
7
7
8
8
9
10
11
12
13
14
15
16
17
17
18
19
19

Never injected
(n of 91)

Subscapularis
37
Rhomboids
46
Levator scapulae
38
Teres minor and infraspinatus
41
Extensor Digitorum
45
Extensor carpi radialis longus or brevis
43
Extensor carpi ulnaris
44
Latissimus dorsi
38
Extensor pollicus longus or brevis
40
Supinator
33
Opponens pollicis
26
Teres Major
29
Triceps
28
Abductor pollicus longus
26
Lumbricals
21
Adductor pollicus brevis
18
Pronator quadratus
13
Pronator teres
12
Pectoralis major
10
Flexor pollicis brevis or longus
5
Flexor carpi ulnaris
3
Flexor carpi radialis
3
Brachioradialis
2
Brachialis
2
Flexor digitorum profundus or
4
superficialis
Biceps
20
1
*If the sum of values was the same for different items, the same rank was used.

Don’t Know
(n of 91)
26
17
27
17
15
17
16
19
15
14
17
17
9
15
10
14
15
11
3
8
6
7
8
8
7
3

Table 5: Assessment use and perceived relevance
Assessment Name

Penn Spasm Scale
London Handicap Scale
Re-integration to Normal
Living Index
Rankin Scale
Warrtenberg Pendulum
Test
Patient Rated Wrist
Evaluation
Wolf Motor Function Test
ArMA Activity Measure
Assessment of Motor and
Process Skills (AMPS)
Box and Block

Rank of least to
most frequently
used
assessment
Low =1
High= 26*
(n=item
respondents)

Rank of least
to most
relevant
assessment
Low =1
high =27*
(n=item
respondents)

Therapists who
never use
assessment
n (% of
frequency of
use n= item
respondents )

Therapists who
have never
heard of
assessment
n (% of
frequency of
use n= item
respondents )

Therapists
unable to judge
relevance of
assessment
n (% of
relevance rating
n=item
respondents)

4 (78)
2 (80)
6 (78)

28 (34)
26 (32)
33 (40)

3 (80)
3 (82)

4 (78)
1 (79)

49 (61.5)
26 (32)

28 (35)
54 (66)

63 (81)
71 (90)

4 (83)

3 (77)

32 (38.5)

48 (58)

66 (85.5)

5 (82)
5 (81)

7 (78)
5 (80)

39 (47.5)
26 (32)

39 (47.5)
51 (63)

60 (77)
71 (89)

6 (78)

9 (78)

57 (73)

16 (20.5)

52 (66.5)

6 (81)

8 (78)

43 (53)

32 (39.5)

56 (72)

29 (36)
44 (53)
15 (1.5)

55 (72)
57 (74)
43 (56)

19 (24)

52 (66)

2 (2.5)
16 (19.5%)
11 (13)
1 (1)
6 (7.2)

22 (29)
37 (47)
32 (41)
25 (31.5)
28 (34)

5 (6)
3 (3.5)

16 (21)
10 (12.5)

3 (3.5)
5 (6)

8 (10)
9 (11.5)

2 (2.5)

12 (15)

8(9.5)
2 (2.5)

15 (19)
5 (6.5)

0 (0)
1 (1)
0 (0)

9 (11.5)
6 (7.5)
4 (5)

1 (82)
2 (81)
2 (82)

Motor Activity Log
7 (81)
10 (77)
44 (54.5)
Spasm Frequency Scale
8 (83)
8 (77)
30 (36)
Range of Motion- Torque- 9 (82)
12 (77)
54 (66)
Controlled Goniometry
Disabilities of the Arm,
10 (80)
11 (79)
43 (54)
Shoulder and Hand
Questionnaire (DASH)
Barthel Index
11 (83)
14 (78)
60 (72)
Action Research Arm Test 12 (82)
13 (79)
39 (47.6)
Purdue Peg Board
13 (83)
15 (78)
40 (48)
Ashworth Scale
14 (83)
16 (80)
44 (53)
Canadian Occupational
15 (83)
19 (82)
38 (46)
Performance Measure
Nine-Hole Peg Test
16 (82)
18 (76)
30 (36.5)
Functional Independence
17 (84)
18 (80)
41 (49)
Measure
Goal Attainment Scale
18 (84)
25 (80)
24 (28.6)
Pain Visual Analogue
19 (83)
23 (79)
14 (17)
Scale
Motor Assessment
20 (86)
20 (80)
19 (22)
Scale(MAS) or UL MAS
Modified Tardieu Scale
21 (84)
22 (79)
15 (18)
Manual Muscle test
22 (84)
21 (78)
11 (13)
(muscle strength rating)
Tardieu Scale
23 (87)
26 (79)
26 (30)
Modified Ashworth Scale
24 (85)
24 (82)
9 (10.5)
Range of Motion26 (88)
27 (80)
7 (8)
Goniometry
*Derived from sum of response values; equal sum scores given equal rank

53 (65.5)
54 (66.5)
46 (56)

67 (86)
69 (86)
65 (83)

Action Research Arm Test: Hsieh CL, Hsueh IP, Chiang FM & Lin PH. (1998). Inter-rater
reliability and validity of the Action Research Arm test in stroke patients. Age & Ageing 27:107-14.
Arm Activity Measure*: Ashford S, Slade M, Turner-Stokes L. (2013) Conceptualisation and
development of the arm activity measure (ArmA) for assessment of activity in the hemiparetic arm.
Disability and Rehabilitation. (2013) DOI: 10.3109/09638288.2012.743602
Arm Activity Measure*: Ashford, S. Slade, M. Turner-Stokes, L. (2010) Development of the
Arm Activity measure (ArmA) for assessment of activity in the hemiplegic arm. Chartered Society of
Physiotherapy Congress. Liverpool, October 15-16.
Ashworth Scale : Ashworth B (1964). Preliminary trial of carisoprodol in multiple sclerosis.
Practitioner 192:540-542
Ashworth Scale: Damiano DL, Quinlivan JM, Owen BF, Payne P, Nelson KC, Abel MF
(2002). What does the Ashworth Scale really measure and are instrumented measures more valid
and precise? Developmental Medicine & Child Neurology, 44:112-118

Assessment of Motor Processes and Skills : Fisher AG. (1995). Assessment of motor and
process skills. Fort Collins (CO): Three Star Press
Barthel Index : Wade DT & Collin C. (1988).The Barthel ADL Index: A standard measure
of physical disability? Disability and Rehabilitation. 10: 64- 67.
Box & Block Test : Mathiowetz V, Volland G, Kashman N & Weber K. (1985). Adult norms for
the Box and Block Test of manual dexterity. American Journal of Occupational Therapy, 39, 386-391.
Canadian Occupational Performance Measure: Law M, Baptiste S, McColl MA, Opzoomer A,
Polatajko H, & Pollock N. (1990). The Canadian occupational performance measure: an outcome
measure for occupational therapy. Canadian Journal of Occupational Therapy, 57: 2 82-87
Disability of the Arm, Shoulder, Hand : Hudak PL, Amadio PC , Bombardier C, Beaton D, Cole
D, Davis A, Hawker G, Katz, JN, Makela M, Marx RG, Punnett L, & Wright J. (1996). Development of
an upper extremity outcome measure: The DASH (Disabilities of the Arm, Shoulder, and Head).
American Journal of Industrial Medicine, 29: 602–608
Functional Independence Measure : Keith RA, Granger CV, Hamilton BB, & Sherwin FS.
(1987). The functional independence measure: a new tool for rehabilitation. Advances in Clinical
Rehabilitation, 1: 6-18.
Goal Attainment Scale : Turner-Stokes L, Williams H, Johnson J. (2009). Goal attainment
scaling: does it provide added value as a person-centered measure for evaluation of outcome in
neurorehabilitation following acquired brain injury? Journal of Rehabilitation Medicine 41: 528-535
London Handicap Scale : Harwood R, Rogers A, Dickinson E, et al. (1994). Measuring
handicap: the London handicap scale, a new outcome measure for chronic disease. Quality in Health
Care 3: 11–16.
Manual Muscle Test : Mendell JR, Florence J. (1990). Manual muscle testing. Muscle Nerve,
13 (Suppl): S16-20
Modified Ashworth Scale : Bohannon RW, Smith MB (1987).Interrater reliability of a
modified Ashworth scale of muscle spasticity. Physical Therapy 67: 206-207
Modified Tardieu scale : Gracies JM, Marosszeky JE, Renton R, Sandanam J, Gandevia
SC,Burke D. (2000) Short-term effects of dynamic lycra splints on upper limbs in hemiplegic patients.
Archives of Physical Medicine and Rehabilitation 81: 1547–1555.
Motor Activity Log : van der Lee J, Beckerman H, Knol DL, de Vet HCW, Bouter LM. (2004).
Clinimetric properties of the Motor Activity Log for the assessment of arm use in hemiparetic
patients. Stroke. 35: 1–5

Motor Activity Log : Taub E, Morris D, Bowman M, Delgado A, Uswatte G. (1996). UpperExtremity Motor Activity Log [Manual]. Available from Edward Taub, Psychology Department, UAB,
CH415, Birmingham, Ala.
Motor Assessment Scale (Upper Limb items): Carr DL J.H, Shepherd R.B, Nordholm L & Lynne
D. (1985). Investigation of a New Motor Assessment Scale for Stroke Patients. Physical Therapy, 65:
175-180.

Nine-hole Peg Test : Mathiowetz V, Weber K, Kashman N, Volland G. (1985). Adult Norms for
the Nine Hole Peg Test of Finger Dexterity. The Occupational Therapy Journal of Research. 5:24-33.
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